Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Transpl Int. 2011 Jul;24(7):697-707. doi: 10.1111/j.1432-2277.2011.01259.x. Epub 2011 May 9.
Small bowel transplantation (SBT) is becoming a preferred treatment for patients with irreversible intestinal failure. Despite continuous improvement of immunosuppression, SBT is plagued by a high incidence of acute cellular rejection (ACR) that is frequently intractable. Therefore, there is a need for reliable detection markers and novel immunosuppressive strategies that can achieve better control of ACR. We hypothesized that particular transcriptomes provide critical regulation of the intragraft immune response. The aim of our study was to detect potential molecular biomarkers for identifying ACR in minute mucosal biopsies. We examined 30 intestinal mucosal biopsies (AR/NR; 17/13) obtained from recipients after SBT or multivisceral transplantation. We utilized TaqMan® Gene Signature Arrays (immune, inflammation and apoptosis) and investigated the expression of 280 genes. As one of our validations, we performed immunohistochemistry for selected targets. We detected 252 mRNAs in total, 92 of which were found with significantly different expression levels between the AR and NR groups. Immunohistochemistry showed significantly increased staining for IL1R2, ICAM1, GZMB, and CCL3 (P < 0.05) during ACR. For the first time, we characterize the potential molecular changes that are associated with modulation of histological appearances of intestinal ACR. These differences in transcriptome patterns can be used to identify robust biomarkers and potential novel therapeutic targets for immunosuppressive agents.
小肠移植(SBT)正成为不可逆性肠衰竭患者的首选治疗方法。尽管免疫抑制不断改善,但 SBT 仍受到急性细胞排斥(ACR)发生率高的困扰,且通常难以治疗。因此,需要可靠的检测标志物和新的免疫抑制策略,以更好地控制 ACR。我们假设特定的转录组为移植物内免疫反应的关键调节提供了依据。本研究旨在检测微小黏膜活检中识别 ACR 的潜在分子生物标志物。我们检查了 30 例小肠黏膜活检(AR/NR;17/13),这些活检取自 SBT 或多器官移植后的受者。我们使用 TaqMan®基因表达谱芯片(免疫、炎症和细胞凋亡),并研究了 280 个基因的表达情况。作为验证之一,我们对选定的靶基因进行了免疫组织化学检测。我们总共检测到 252 个 mRNA,其中 92 个在 AR 和 NR 组之间的表达水平有显著差异。免疫组织化学显示,在 ACR 期间,IL1R2、ICAM1、GZMB 和 CCL3 的染色显著增加(P<0.05)。这是首次对与肠道 ACR 组织学表现调节相关的潜在分子变化进行特征描述。这些转录组模式的差异可用于识别稳健的生物标志物和潜在的新型免疫抑制剂治疗靶点。